Sentinel node biopsy should be offered in thin melanoma with mitotic rate greater than one

Dermatologic Surgery

Volumn 37, Issue 8, 2011, Pages 1080-1088

  Sekula Gibbs, Shelley A ^a   Shearer, Melissa A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; HUMAN; MELANOMA; MITOSIS RATE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; SENTINEL LYMPH NODE BIOPSY; TREATMENT INDICATION; TUMOR VOLUME;

HUMANS; LYMPHATIC METASTASIS; MELANOMA; MITOTIC INDEX; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 79961021743     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2011.02015.x     Document Type: Article

References (42)

1. Balch C, Buzaid A, Soong S, Atkins MB, et al,. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48. (Pubitemid 32786276)
2. Balch C, Gershenwald J, Soong S, Thompson JF, et al,. Final Version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
3. Clark W, From L, Bernardino E, Mihm MC,. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29: 705-27.
4. Johnson T, Bradford C, Gruber S, Sondak VK, et al,. Staging workup, sentinel node biopsy, and follow-up tests for melanoma. Arch Dermatol 2004; 140: 107-13. (Pubitemid 38090277)
5. Stebbins W, Garibyan L, Sober A., Sentinel lymph node biopsy and melanoma: 2010 update Part I. J Am Acad Dermatol 2010; 62: 723-34.
6. Stebbins W, Garibyan L, Sober A., Sentinel lymph node biopsy and melanoma: 2010 update Part II. J Am Acad Dermatol 2010; 62: 737-48.
7. Kesmodel S, Karakousis G, Botbyl J, Canter RJ, et al,. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 2005; 12: 449-58. (Pubitemid 40884259)
8. Azzola M, Shaw H, Thompson J, Soong SJ, et al,. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003; 97: 1488-98. (Pubitemid 36297779)
9. Gimotty P, Elder D, Fraker D, Botbyl J, et al,. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007; 25: 1129-34. (Pubitemid 46596766)
10. Sondak V, Taylor J, Sabel M, Wang Y, et al,. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004; 11: 247-58. (Pubitemid 40486764)
11. Barnhill R, Katzen J, Spatz A, Fine J, et al,. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol 2005; 32: 268-73. (Pubitemid 40459928)
12. Markovic S, Erickson L, Rao R, Weenig RH, et al,. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc 2007; 82: 490-513. (Pubitemid 46543475)
13. Scolyer R, Shaw H, Thompson J, Li LX, et al,. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol 2003; 27: 1571-6. (Pubitemid 37486620)
14. Payette M, Katz M, Grant-Kels J., Melanoma prognostic factors found in the dermatopathology report. Clin Dermatol 2009; 27: 53-74.
15. Piris A, Mihm M., Progress in melanoma histopathology and diagnosis. Heamtol Oncol Clin N Am 2009; 23: 467-80.
16. Cascinelli N, Belli F, Santinami M, Fait V, et al,. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2003; 7: 469-74.
17. Cascinelli N, Bombardieri E, Bufalino R, Camerini T, et al,. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol 2006; 24: 4464-71. (Pubitemid 46630985)
18. Gershenwald J, Mansfield P, Lee J, Ross MI,. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (>or=4 mm) primary melanoma. Ann Surg Oncol 2000; 7: 160-5. (Pubitemid 30164687)
19. Dessureault S, Soong S, Ross M, Thompson JF, et al,. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 2001; 8: 766-70. (Pubitemid 34003324)
20. Ferrone C, Panageas K, Busam K, Brady MS, et al,. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 2002; 9: 637-45. (Pubitemid 34857980)
21. Rousseau D, Ross M, Johnson M, Prieto VG, et al,. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 2003; 10: 569-74. (Pubitemid 40486922)
22. Balch C, Morton D, Gershenwald J, McMasters KM, et al,. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol 2009; 60: 872-5.
23. ™, go on-line to.
24. Filho R, Ferreira L, Biasi L, Enokihara MM, et al,. Vertical growth phase and positive sentinel node in thin melanoma. Brazilian J Med Biol Res 2003; 36: 347-50. (Pubitemid 36442984)
25. Paek S, Griffith K, Johnson T, Sondak VK, et al,. The impact of factors beyond Breslow depth predicting sentinel lymph node positivity in melanoma. Cancer 2007; 109: 100-8. (Pubitemid 46120199)
26. Kruper L, Spitz F, Czerniecki B, Fraker DL, et al,. Predicting sentinel lymph node status in AJCC Stage I/II primary cutaneous melanoma. Cancer 2006; 107: 2436-45. (Pubitemid 44748527)
27. Karakousis G, Gimotty P, Botbyl J, Kesmodel SB, et al,. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol 2006; 13: 533-41.
28. Bleicher R, Essner R, Foshag L, Wanek LA, et al,. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003; 21: 1326-31. (Pubitemid 46606411)
29. McMasters K, Reintgen D, Ross M, Gershenwald JE, et al,. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 2001; 19: 2851-5. (Pubitemid 32538194)
30. Morton D, Thompson J, Essner R, Elashoff R, et al,. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg 1999; 230: 453-65. (Pubitemid 30191840)
31. Gershenwald J, Thompson W, Mansfield P, Lee JE, et al,. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976-83. (Pubitemid 29109331)
32. Morton D, Cochran A., The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. Br J Dermatol 2004; 151: 308-19. (Pubitemid 39215144)
33. Balch C, Soong S, Gershenwald J, Thompson JF, et al,. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-34. (Pubitemid 32786275)
34. Miranda E, Gertner M, Wall J, Grace E, et al,. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 2004; 139: 831-6.
35. Tsao H, Feldman M, Fullerton J, Sober AJ, et al,. Early detection of asymptomatic pulmonary melanoma mestastases by routine chest radiographs is not associated with improved survival. Arch Dermatol 2004; 140: 67-70. (Pubitemid 38090272)
36. Hafner J, Schmid M, Kempf W, Burg G, et al,. Baseline staging in cutaneous malignant melanoma. Br J Dermatol 2004; 150: 677-86. (Pubitemid 38586218)
37. Wang T, Johnson T, Cascade P, Redman BG, et al,. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 2004; 51: 399-405. (Pubitemid 39178667)
38. Johnson T, Sondak V, Bichakjian C, Sabel MS,. The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol 2006; 54: 19-27. (Pubitemid 41832454)
39. van Akkooi A, de Wilt J, Verhoef C, Graveland WJ, et al,. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer 2006; 42: 372-80. (Pubitemid 43132893)
40. Morton D, Cochran A, Thompson J, Elashoff R, et al,. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005; 242: 302-13. (Pubitemid 41306595)
41. Morton D, Hoon D, Cochran A, Turner RR, et al,. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003; 238: 538-50. (Pubitemid 38176391)
42. Vuylsteke R, van Leewen P, Statius Muller MG, Gietema HA, et al,. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol 2003; 21: 1057-65. (Pubitemid 46594135)